#Anixa Biosciences #Ovarian Cancer #CAR-T Technology

Anixa Biosciences to Present at ASCO 2025

Anixa Biosciences, Inc. (NASDAQ: ANIX) is set to make a significant impact in the oncology field with a presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled for June 2, 2025, in Chicago, Illinois, Dr. Pamela D. Garzone, Chief Development Officer, will showcase a poster detailing a groundbreaking Phase 1 clinical trial focused on ovarian cancer.

The presentation is titled "Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)." The lead author of the study is Dr. Robert Wenham, who chairs the Gynecologic Oncology Program at Moffitt Cancer Center and serves as the principal investigator for the trial.

Presentation Details

• - Session: Developmental Therapeutics—Immunotherapy
• - Session Type: Poster Session
• - Date & Time: June 2, 2025, from 1:30 PM to 4:30 PM CT
• - Abstract ID: TPS2682

This clinical trial represents a novel approach to ovarian cancer treatment through innovative CAR-T therapy, specifically targeting the FSH receptor. Anixa’s unique therapeutic strategy utilizes chimeric endocrine receptor-T cell (CER-T) technology that sets it apart from traditional CAR-T therapies. In this trial, the natural ligand of the FSH receptor does not bind directly through an antibody fragment but instead utilizes follicle-stimulating hormone (FSH), highlighting an ingenious way to engage the immune system in targeting tumor cells.

Anixa has entered a strategic collaboration with the Moffitt Cancer Center, known for its leadership in cancer immunotherapy. This partnership aims to leverage advanced technologies to develop next-generation cellular therapies, employing rights to pioneering treatments such as CAR-T and tumor-infiltrating lymphocytes (TILs).

In addition to ovarian cancer, Anixa’s drug development process extends to other malignancies through its vaccine programs in conjunction with the Cleveland Clinic. These vaccines are designed to prevent and treat breast and ovarian cancers and also include initiatives targeting lung, colon, and prostate cancers. Each vaccine aims at disarming